Key Points Clearmind Medicine Inc. received unanimous approval from an independent Data and Safety Monitoring Board to advance its CMND-100 Phase I/II trial. The decision…
Sagimet Biosciences (NASDAQ: SGMT) shares moved higher after the company’s China partner, Ascletis Pharma, reported positive topline results from a long-term Phase 3 safety study…
Clearmind Medicine Inc. (Nasdaq: CMND) a clinical stage biotech company developing psychedelic-derived treatment solutions, today announced the initiation of its Phase I/IIa clinical trial at the…